The Open Hypertension Journal
2018, 10 : 8-14Published online 2018 March 30. DOI: 10.2174/1876526201810010008
Publisher ID: TOHYPERJ-10-8
RESEARCH ARTICLE
Features of the Lipid Profile in Patients with Arterial Hypertension and Cardiovascular Diseases According to Smoking Status
2 Department of Preventive Pharmacotherapy, , ,
3 Department of Clinical Pharmacology, Russian National Research Medical University N.I. Pirogov,Russia
* Address correspondence to this author at the Russian National Research Medical University N.I. Pirogov, Ostrovityanov str. 1, Moscow, Russia, 117997; Tel: +79153204379; E-mail: anti23@mail.ru
ABSTRACT
Introduction:
Smoking is a risk factor for cardiovascular diseases. The direct influence of smoking status on the lipid profile was highlighted in patients with arterial hypertension and associated cardiovascular disease.
Objective:
We aimed to evaluate lipid profile among patients related to smoking status in a registry-based cohort study.
Methods:
The data of registry of National Research Сenter of Preventive Medicine were conducted. Patients filled in the special questionnaire in order to identify their smoking status, statins therapy.
Results:
274 patients were included; main nosologic disease was arterial hypertension (230 patients), 14.8% were smokers, 62.9% non-smokers, and 22.2% past-smokers. The rank analysis of variations by Kruskal-Wallis (H) test for multiple comparisons between groups revealed significant differences in lipid levels for patients according to smoking status: total cholesterol H (2, n=234) =9.119, p=0.0105; LDL-cholesterol H (2, n=225) =6.2615, p=0.0437; triglycerides H (2, n=216) =9.8485, p=0.0073; these indicators of lipid profile among non-smoking patients were lower than among smokers, these indices among past-smokers were lower than among smokers. The absence of statistically significant differences between groups was confirmed in statin therapy (χ2 =3.169, df=4, p=0.529). Logistic regression analysis was conducted to identify factors that influence achievement target lipid levels. Only 2 statistically significant signs were identified in this model: smoking (OR 0.1; 95%CI [0.13;4.87]; p=0.03) and statin therapy (OR 8.2;95%CI [-3.6; -,078]; p=0.002).
Conclusion:
Significantly higher lipid levels have been observed in smokers compared to non-smokers in patients with arterial hypertension and associated cardiovascular disease. Smoking is a great factor disincentive to achieve target lipid levels.